Andere Kunden interessierten sich auch für
![Clarithromycin Immediate Release Tablet]( "Clarithromycin Immediate Release Tablet")
Clarithromycin Immediate Release Tablet48,99 €![Extended Release Tablet of Glipizide]( "Extended Release Tablet of Glipizide")
Extended Release Tablet of Glipizide36,99 €![Extended Release Tablet Of Antidiabetic Drug]( "Extended Release Tablet Of Antidiabetic Drug")
Extended Release Tablet Of Antidiabetic Drug40,99 €![Development of Sustained Release Tablet containing Antidiabetic Agent]( "Development of Sustained Release Tablet containing Antidiabetic Agent")
Development of Sustained Release Tablet containing Antidiabetic Agent36,99 €![Sustained Release Matrix Tablet of Cefuroxime Axetil]( "Sustained Release Matrix Tablet of Cefuroxime Axetil")
Sustained Release Matrix Tablet of Cefuroxime Axetil32,99 €![Sustain Release Matrix Tablet of Cinnarizine]( "Sustain Release Matrix Tablet of Cinnarizine")
Sustain Release Matrix Tablet of Cinnarizine32,99 €![Sustained Release Tablet of Itopride Hydrochloride]( "Sustained Release Tablet of Itopride Hydrochloride")
Sustained Release Tablet of Itopride Hydrochloride38,99 €
The book involves a research work towards developing a formulation of anti-osteoporotic drug, which has in-vitro dissolution profile similar to that of the Innovators' formulation. The patents for dosage form of Raloxifene will expire in late future. Hence, our target was to develop a dosage form as that of Innovator product to file an ANDA application. The present study involves the development of a non-infringing formula for an orally administrable immediate release tablet of the anti-osteoporotic drug with reproducible and robust process. The objectives of the research work included (i) formulation and optimization of the coated tablets of Raloxifene with the aid of design of experiment; (ii) enhance dissolution and evaluate release kinetics of drug from the formulation; (iii) comparison of dissolution profiles of developed formulation with innovator product.